Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
PaperCitations, authors & open-access status
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 60 citations, 2016 year and bronze oa status.
60
Citations
2016
Year
bronze
OA Status